Perspective Therapeutics, Inc. Share Price
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
01:30:00 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 3.130 USD | +0.32% |
|
+0.64% | +13.82% |
| 19/08 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 14/08 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
| Market Cap | 36Cr 31Cr 29Cr 26Cr 49Cr 3.38TCr 49Cr 342.66Cr 132.45Cr 1.73TCr 134.18Cr 131.25Cr 5.51TCr | P/E 2026 * |
-3.13x | P/E 2027 * | -2.97x |
|---|---|---|---|---|---|
| Enterprise Value | 19Cr 16Cr 15Cr 14Cr 26Cr 1.8TCr 26Cr 182.93Cr 71Cr 923.79Cr 72Cr 70Cr 2.94TCr | EV / Sales 2026 * |
569x | EV / Sales 2027 * | 319x |
| Free-Float |
89.27% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CATX | Delayed | |
CBOE
| CATX | Real-time | |
|
Tradegate
| AAJ0 | Real-time | |
|
Boerse Muenchen
| AAJ0 | Real-time | |
|
Deutsche Boerse AG
| AAJ0 | Delayed | |
|
Börse Stuttgart
| AAJ0 | Delayed |
Last Transcript : Perspective Therapeutics, Inc.
| 1 day | +0.32% | ||
| 1 week | +0.64% | ||
| Current month | -0.95% | ||
| 1 month | +5.39% | ||
| 3 months | +3.30% | ||
| 6 months | -37.02% | ||
| Current year | +13.82% |
| 1 week | 3.02 |  | 3.24 |
| 1 month | 2.94 | | 3.56 |
| Current year | 2.25 | | 6.16 |
| 1 year | 1.96 | | 6.16 |
| 3 years | 1.6 | | 19.05 |
| 5 years | 1.6 | | 19.05 |
| 10 years | 1.6 | | 28.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Johan Spoor
CEO | Chief Executive Officer | 54 | 05/02/2023 |
Joel D. Sendek
DFI | Director of Finance/CFO | 59 | 04/09/2025 |
Paul Lyne
CTO | Chief Tech/Sci/R&D Officer | - | 08/07/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Johan Spoor
BRD | Director/Board Member | 54 | 05/02/2023 |
Lori Woods
CHM | Chairman | 63 | 03/02/2023 |
| Director/Board Member | 60 | 05/02/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/09/26 | Sell | Company | -35,769 | 0.0313% | ||
| 31/08/26 | Sell | Company | -78,145 | 0.0685% | ||
| 02/03/26 | Free | Director | 50,000 | 0.0439% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.32% | +0.64% | -9.54% | -20.68% | 36Cr | |
| -1.16% | -2.77% | -1.68% | +13.85% | 4.89TCr | |
| -0.40% | +1.03% | +418.57% | +527.30% | 4.5TCr | |
| -1.42% | +2.30% | +42.67% | +22.37% | 4.41TCr | |
| -1.22% | -2.31% | +4.82% | +77.49% | 4.07TCr | |
| -0.96% | -2.31% | +15.75% | +45.41% | 3.35TCr | |
| -0.21% | +9.14% | - | - | 1.78TCr | |
| -0.35% | -1.56% | +21.42% | +120.75% | 1.65TCr | |
| -1.54% | -1.30% | +12.02% | +31.14% | 1.47TCr | |
| -1.65% | -1.03% | +75.93% | +41.12% | 1.38TCr | |
| Average | -0.83% | +0.50% | +64.44% | +95.42% | 2.75TCr | |
| Weighted average by Cap. | -0.95% | +0.05% | +89.05% | +128.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 3L 3L 2L 5L 3.17Cr 5L 32.17L 12.44L 1.62Cr 12.6L 12.32L 5.18Cr | 4L 3L 3L 3L 5L 3.75Cr 5L 38L 14.69L 1.92Cr 14.88L 14.55L 6.11Cr |
| Net income | -12Cr -9.94Cr -9.35Cr -8.53Cr -16Cr -1.09TCr -16Cr -110.84Cr -43Cr -559.75Cr -43Cr -42Cr -1.78TCr | -14Cr -12Cr -11Cr -9.99Cr -19Cr -1.28TCr -19Cr -129.72Cr -50Cr -655.06Cr -51Cr -50Cr -2.09TCr |
| Net Debt | -17Cr -14Cr -13Cr -12Cr -23Cr -1.58TCr -23Cr -159.73Cr -62Cr -806.63Cr -63Cr -61Cr -2.57TCr | -23Cr -20Cr -19Cr -17Cr -32Cr -2.18TCr -32Cr -221.41Cr -86Cr -1.12TCr -87Cr -85Cr -3.56TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | $3.130 | +0.32% | 13,65,189 |
| 03/26/03 | $3.120 | +0.65% | 9,31,703 |
| 02/26/02 | $3.100 | 0.00% | 8,64,638 |
| 01/26/01 | $3.100 | -1.90% | 7,05,838 |
| 31/26/31 | $3.160 | +1.61% | 9,10,730 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CATX Stock
Select your edition
All financial news and data tailored to specific country editions
